1394076-92-6
1394076-92-6
Chemical Structure
GNE-317
- CAS No.: 1394076-92-6
- Formula:C19H22N6O3S
- Molecular Weight:414.48
IUPAC Name: 5-(6-(3-methoxyoxetan-3-yl)-7-methyl-4-morpholinothieno[3,2-d]pyrimidin-2-yl)pyrimidin-2-amine
InChIKey: XOZLHJMDLKDZAL-UHFFFAOYSA-N
SMILES: NC1=NC=C(C2=NC(N3CCOCC3)=C4C(C(C)=C(C5(OC)COC5)S4)=N2)C=N1
Biological Activity: GNE-317 is a PI3K/mTOR inhibitor, is able to cross the blood-brain barrier (BBB).
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
GNE-317 | 98.76% | GNE-317 is a PI3K/mTOR inhibitor, is able to cross the blood-brain barrier (BBB). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PI-540 | PI-540 is a bicyclic thienopyrimidine derivative and an orally active PI3K inhibitor. PI-540 has anti-cancer cell proliferation properties and high tissue distribution. PI-540 can inhibit different isoforms of PI3K, with IC50s of 10 nM (P110α), 3510 nM (P110β), 410 nM (P110δ), and 33110 nM (P110γ). PI-540 also inhibits mTOR (IC50: 61 nM) and DNA-PK (IC50: 525 nM). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GNE-493 | 99.81% | GNE-493 is a potent, selective, and orally available dual pan-PI3-kinase/mTOR inhibitor with IC50s of 3.4 nM, 12 nM, 16 nM, 16 nM and 32 nM for PI3Kα, PI3Kβ, PI3Kδ, PI3Kγ and mTOR. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GNE-490 | 96.79% | GNE-490, a (thienopyrimidin-2-yl)aminopyrimidine, is a potent pan-PI3K inhibitor with IC50s of 3.5 nM, 25 nM, 5.2 nM, 15 nM for PI3Kα, PI3Kβ, PI3Kδ and PI3Kγ, respectively. GNE-490 has >200 fold selectivity for mTOR (IC50=750 nM). GNE-490 shows potent suppression efficacy profile against MCF7.1 breast cancer xenograft model. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GNE-477 | 98.75% | GNE-477 is a potent and efficacious dual PI3K (IC50=4 nM)/mTOR(Ki=21 nM) inhibitor. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Apitolisib | 99.29% | Apitolisib (GDC-0980; GNE 390; RG 7422) is a selective, potent, orally bioavailable Class I PI3 kinase and mTOR kinase (TORC1/2) inhibitor with IC50s of 5 nM/27 nM/7 nM/14 nM for PI3Kα/PI3Kβ/PI3Kδ/PI3Kγ, and with a?Ki?of 17 nM for mTOR. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Fimepinostat | 99.95% | Fimepinostat (CUDC-907) potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes with an IC50 of 19/54/39 nM and 1.7/5.0/1.8/2.8 nM for PI3Kα/PI3Kβ/PI3Kδ and HDAC1/HDAC2/HDAC3/HDAC10 , respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
PI3K/mTOR Inhibitor-8 | PI3K/mTOR Inhibitor-8 (Compound 18b) is a PI3K and mTOR dual inhibitor with IC50 values of 0.46 nM and 12 nM against PI3Kα and mTOR, respectively. PI3K/mTOR Inhibitor-8 induces HCT-116 cells apoptosis and arrests cell cycle at the G1/S phase. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
BET-IN-27 | BET-IN-27 (compound 6C) is an oral BET inhibitor with the IC50 values of 3.3 nM (BRD4-BD2)、3.4 nM (BRD4-BD1)、4.1 nM (BRD2-BD1)、20.4 nM (BRD3-BD1) and 42.0 nM (BRDT-BD1), respectively. BET-IN-27 shows anti-proliferative activity. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Ifupinostat | 99.30% | Ifupinostat (BEBT-908) is a blood-brain barrier-permeable PI3K/HDAC inhibitor. Ifupinostat exerts anticancer activity against hematologic malignancies, lung cancer, colon cancer, brain cancer and other cancers. Ifupinostat inhibits the PI3K/AKT/mTOR signaling pathway, suppresses c-Myc expression and induces ferroptosis. Ifupinostat can be used in tumor research. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Paxalisib | 99.51% | Paxalisib (GDC-0084) is a brain penetrant inhibitor of PI3K and mTOR, with Kis of 2 nM, 46 nM, 3 nM, 10 nM and 70 nM for PI3Kα PI3Kβ, PI3Kδ, PI3Kγ and mTOR, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
